Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Randi Y. Leavitt"'
Autor:
David S. LEWI, Jamal M. SULEIMAN, David E. UIP, Rogerio J. PEDRO, Rosa A. SOUZA, Grace S. SULEIMAN, Conceição ACCETTURI, Olavo M. LEITE, William B. ABREU, Artur O. KALICHMAN, Joaquim P.P. MORAES-FILHO, Eduardo F. MOTTI, Maria Lucia C. PECORARO, Mark R. MAKURATH, Michael L. NESSLY, Randi Y. LEAVITT
Publikováno v:
Revista do Instituto de Medicina Tropical de São Paulo, Vol 42, Iss 1, Pp 27-36 (2000)
Treatment with indinavir has been shown to result in marked decreases in viral load and increases in CD4 cell counts in HIV-infected individuals. A randomized double-blind study to evaluate the efficacy of indinavir alone (800 mg q8h), zidovidine alo
Externí odkaz:
https://doaj.org/article/d9ea9b7140eb44e181350dc28cc2d4db
Autor:
Randi Y. Leavitt, Anders Viberg, Carolyn R. Cho, Craig Fancourt, Julie A. Stone, Sreeraj Macha, Yoshihiko Murata, Marita Prohn, Cyrus Badshah, Philip Sabato, Kevin Dykstra, Casey Davis
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:485-495
The cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplantation recipients. In a phase III trial (NCT02137772), leter
Autor:
Roy F. Chemaly, Wendy W. Yeh, Per Ljungman, Valerie L Teal, Randi Y. Leavitt, Cyrus Badshah, Hong Wan, Francisco M. Marty, Joan R. Butterton
Publikováno v:
American Journal of Transplantation. 20:1703-1711
Letermovir, a cytomegalovirus (CMV) terminase-complex inhibitor, is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). In a phase III, double-blind, rand
Autor:
Cyrus Badshah, Kathleen M. Mullane, Andrew J. Ullmann, Shariq Haider, Randi Y. Leavitt, Yoshihiko Murata, Francisco M. Marty, Johan Maertens, Per Ljungman, Hong Wan, Michael Boeckh, Emily A. Blumberg, Sanjeet Dadwal, Yuta Katayama, Roy F. Chemaly, Nicholas A. Kartsonis, David R. Snydman, Hermann Einsele, Yoshinobu Kanda, Mark J. DiNubile, Rafael F. Duarte, Janice M. Brown, Valerie L Teal
Publikováno v:
New England Journal of Medicine. 377:2433-2444
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we r
Autor:
Gary Fahle, Robin K. Avery, Debra Birnkrant, Jeffrey C. Murray, Yoshihiko Murata, Mary Singer, Randi Y. Leavitt, Hans H. Hirsch, Lynn Fallon, Francisco Martinez-Murillo, John E. McKinnon, Gavin Cloherty, Randall Lanier, Rekha Abichandani, Philip R. Krause, Sally Mossman, M Michelle Berrey, Wael Saber, Ali Alghamdi, John A. D. Leake, Raymund R. Razonable, Takashi E. Komatsu, Emily A. Blumberg, Mahmood Tazari, Kurt Gunter, Thomas Mertens, Jens D Lundgren, Yoichiro Natori, Sunwen Chou, Kevin Modarress, Jay Erdman, Li Li, Terry Bowlin, Peter W. Hunt, William Cruikshank, Anna Wijatyk, Frank Kuhr, Garrett Nichols, Aimee Hodowanec, Marcie L. Riches, Shahid Husain, Karl S. Peggs, Jules O'Rear, Johann Mols, Filip Josephson, Christopher Lademacher, Paul Baum, Bernhardt Zeiher, Paul D. Griffiths, Susan Barnett, Mark N. Prichard, Michael Boeckh, Roy F. Chemaly, Megan McCutcheon, Thomas Stamminger, Fausto Baldanti, Chalom Sayada, Veronica Miller, Andreas Pikis, Atul Humar, Dimitri Gonzalez, Barbara D. Alexander, Jennifer Brooks, Jeff Roberts, Camille N. Kotton, Hermann Einsele, Tadd Lazarus, David Boutolleau, Deepali Kumar, Sandra Nusinoff Lehrman, Ani Orchanian-Cheff, Howard Mayer, Heather Gillis, Dong Yu, David Murawski, Per Ljungman, Paula Isabelle Lodding, Lesia K. Dropulic
Publikováno v:
Clinical Infectious Diseases. 66:617-631
Symptomatic cytomegalovirus (CMV) disease has been the standard endpoint for clinical trials in organ transplant recipients. Viral load may be a more relevant endpoint due to low frequency of disease. We performed a meta-analysis and systematic revie
Autor:
Cyrus Badshah, Nicholas A. Kartsonis, Hong Wan, Michael Schmitt, Johan Maertens, Francisco M. Marty, Randi Y. Leavitt, Joan R. Butterton, Valerie L Teal, Roy F. Chemaly, Per Ljungman, Yoshihiko Murata, Kendra Sarratt
Publikováno v:
Clin Infect Dis
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background In a phase 3 trial, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause mortality at week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients. This p
Autor:
Brenda Homony, Claudine Duvivier, I Neves, Christine Katlama, Gordon Crofoot, Natalia Zakharova, Stefan Esser, Hedy Teppler, Xia Xu, Randi Y. Leavitt, Adriano Lazzarin, CR Mejia, M Mustafa, Olga Aleksandrovna Tsybakova, James H McMahon, Brian Conway, Juan Carlos Rondon, Faiza Ajana, TS Chow, M Oyanguren, EM Rojas, Jean-Michel Molina, A Avihingsanon, Carlos Perez, Koldo Aguirrebengoa, Karen T. Tashima, M Wolff, Yazdan Yazdanpanah, Eugenia Negredo, R Serrao, Richard James Moore, Carmen D. Zorrilla, Winai Ratanasuwan, C Echiverri, L Panther, Joel E. Gallant, Andri Rauch, HH Lin, Bernard Vandercam, Anthony John Scarsella, L Hercilla, A. Antinori, Pedro Cahn, Albrecht Stoehr, DE Sweet, Mariette E. Botes, Johannes R. Bogner, Hans Jaeger, Soumi Gupta, Olaf Degen, Nathan Clumeck, H. Hartl, PJ Ruane, Ckc Lee, Juergen K. Rockstroh, Richard Kaplan, N Roth, MF Lasso, Rassool, Gatell Jm, Markus Bickel, Nelson, M Moutschen, V Sotnikov, R Kaplan, Amanda Clarke, WH Sheng, Anchalee Avihingsanon, Doug Ward, L Vanderkerckhove, Daniel S Berger, Sasisopin Kiertiburanakul, Ghr Smith, Sandy L. Rawlins, Mohammed Rassool, A d'Arminio Monforte, Paul E. Sax, Margaret A. Johnson, F. Maggiolo, Fernando Maltez, Ramirez, Evgeny Voronin, Eyal Shahar, S Henn, Cheryl McDonald, A Ustianowski, MT Bloch, E Arathoon, Peter Sklar, LD Gonzalez, Enrique Ortega, Louis Sloan, Amneris E. Luque, Isabelle Poizot-Martin, M. H. Losso, Giuliano Rizzardini, Debbie Hagins, Lilly East, Andrea Gori, Matthias Cavassini, Princy Kumar, Isabel Cassetti, G. Di Perri, Benedetto Maurizio Celesia, Evelyn Rojas, S Ferret, Jerry L. Cade, KM Mullane, CB Hsiao, Dane Turner, Eugénio Teófilo, Bach-Yen Nguyen, Craig A. Dietz, Anthony Rodgers, Elena Orlova-Morozova, Z. Sthoeger, Jean-Guy Baril, Hila Elinav, I Khaertynova, JG Saraiva da Cunha, Carl J. Fichtenbaum, G Faetkanheuer, Peter Ruane, HC Tsai, R Iskandar Shah Raja Azwa, Lerato Mohapi, Firaya Nagimova, Keikawus Arastéh, J. Durant, JD Velez, Jacques Reynes, ST Lewis, Saag, Otto Sussmann, P. Cahn, D Changpradub, Mark Bloch, RM Novak, W Ratanasuwan, Kathleen Squires, Fiona Smaill, Larissa Wenning, Jose R. Arribas, Edwin DeJesus, Don Smith, JO Morales, A. Yakovlev, Sharon Walmsley, Carolina Eugenia Chahin, I Levy, Alexandra Calmy, David James Prelutsky, David M. Asmuth, Linos Vandekerckhove, J Troya, Antonio Antela, Alan Winston, Lizette Santiago, Juan Berenguer, Marcel Stoeckle, RA Castillo, Anita Rachlis
Publikováno v:
Lancet HIV
Lancet HIV, Elsevier, 2017, 4 (11), pp.e486-e494. ⟨10.1016/S2352-3018(17)30128-5⟩
LANCET HIV
The Lancet HIV, Vol. 4, No 11 (2017) pp. e486-e494
Lancet HIV, Elsevier, 2017, 4 (11), pp.e486-e494. ⟨10.1016/S2352-3018(17)30128-5⟩
LANCET HIV
The Lancet HIV, Vol. 4, No 11 (2017) pp. e486-e494
Summary Background Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. Methods In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b080de940b6244d90b7b170ca487b8b0
https://hal.archives-ouvertes.fr/hal-01745628
https://hal.archives-ouvertes.fr/hal-01745628
Autor:
Roy F. Chemaly, Francisco M. Marty, Valerie L Teal, Cyrus Badshah, Wendy W. Yeh, Per Ljungman, Randi Y. Leavitt, Hong Wan, Joan R. Butterton
Publikováno v:
Open Forum Infectious Diseases
Background LET prophylaxis through HCT Week 14 was highly effective in preventing clinically significant CMV infection (CS-CMVi), had a good safety profile, and was associated with lower all-cause mortality by HCT Week 24 compared with placebo (PBO).
Autor:
Michael F. Para, Jeffrey L. Lennox, Randi Y. Leavitt, Grace A. McComsey, Lumine H. Na, Catherine Godfrey, Susan E. Cohn, Manish Sagar, Heather J. Ribaudo, Francesca T. Aweeka, Todd T. Brown, Daniel R. Kuritzkes, Judith S. Currier, Angelina Villasis-Keever, Raphael J. Landovitz, Bryan Baugh, Kristine B. Patterson, Ighovwerha Ofotokun
Publikováno v:
Clinical Infectious Diseases. 60:1842-1851
Background. Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonav
Autor:
Hedy Teppler, Anthony Rodgers, Mark J. DiNubile, Kathleen Squires, Randi Y. Leavitt, Yazdan Yazdanpanah, Peter Sklar, Linda-Gail Bekker, Yan Zhou, Christine Katlama
Publikováno v:
Open Forum Infectious Diseases
Background Antiretroviral therapy in human immunodeficiency virus (HIV)-infected women and blacks merits particular scrutiny because these groups have been underrepresented in clinical trials. Methods To document the effects of raltegravir across sex